Summary
IDEXX Laboratories, Inc. (IDXX) filed a Form 8-K on July 17, 2017, to announce a change in its Board of Directors. The company elected Stuart M. Essig, PhD, as an independent Class III Director, effective July 12, 2017. This appointment necessitated an increase in the Board's size from eight to nine members, with an additional seat allocated to Class III Directors.
Key Highlights
- 1IDEXX Laboratories appointed Stuart M. Essig, PhD, as an independent Class III Director on July 12, 2017.
- 2The Board of Directors was increased from eight to nine members to accommodate the new director.
- 3The number of Class III Directors was increased from two to three.
- 4Dr. Essig is expected to stand for election by stockholders in 2019.
- 5There are no disclosed related-person transactions involving Dr. Essig.
- 6Dr. Essig will receive compensation consistent with other non-employee directors, with prorated fees for the third quarter of 2017 and prorated stock grants in September 2017.
- 7The company issued a press release on July 17, 2017, detailing this board appointment.
Frequently Asked Questions
IDEXX Laboratories filed this 8-K to report the election of a new independent director, Stuart M. Essig, PhD, to its Board of Directors and related board structure changes.
Stuart M. Essig, PhD, is a newly elected independent Class III Director to the IDEXX Laboratories Board of Directors. He has no disclosed related-person transactions with the company.
Dr. Essig will receive the standard compensation for non-employee directors. His cash fee for the third quarter of 2017 will be prorated, and his annual stock unit and stock option grants, expected in September 2017, will also be prorated to reflect his tenure on the Board.
The election of Dr. Essig increased the total number of directors on the Board from eight to nine. Specifically, the number of Class III Directors increased from two to three.